5-FU + LV

From OncoWiki
Jump to navigationJump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Regimen

Hepatocellular Carcinoma

  • 5-FU 370 mg/m2/d iv d1-5
  • Leucovorin 200 mg/m2/d iv d1-5
  • Q4w

References

Porta, C et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995; 52:487

Indication

Colon Cancer

Roswell park regimen

Adjuvant chemotherapy

  • 5-FU 500 mg/m2 iv bolus
  • Leucovorin 500 mg/m2 iv over 2 hrs
  • Qw x 6 wks every 8 wks for 4 cycles
References

Haller, DG et al. Phase III study of fluorouracil, leucovorin and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005; 23:8671

Mayo clinic regimen

Adjuvant chemotherapy

  • 5-FU 425 mg/m2/d iv bolus d1-5
  • Leucovorin 20 mg/m2/d iv bolus d1-5
  • Q4w x 6 cycles
References

Haller, DG et al. Phase III study of fluorouracil, leucovorin and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005; 23:8671

O'Connell, MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246

Ovarian Epithelial Cancer

Chemotherapy for recurrent or metastatic cancer

  • Leucovorin 200 mg/m2/d iv bolus followed by 5-FU 370 mg/m2/d iv bolus d1-5
  • Q4w

References

Look, KY et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1995; 18:19

Pancreatic Cancer

Adjuvant chemotherapy

  • 5-FU 425 mg/m2/d iv bolus d1-5
  • Leucovorin 20 mg/m2/d iv bolus d1-5
  • Q4w x 6 cycles

References

Neoptolemos, JP et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200